PT-141 Side Effects and Safety
Reported PT-141 side effects, contraindications, and safety signals.
Safety & Contraindications
PT-141 is a research compound and is not FDA-approved for general use. It should be avoided by anyone with uncontrolled hypertension, cardiovascular disease, and pregnancy. Most reported effects are mild and dose-dependent, so start at the low end of the dosing range and titrate up slowly rather than chasing a maximal dose. Injection-site redness, itching, or a temporary lump are the most common local reactions; rotate sites and use clean technique to keep them minimal.
What to Monitor
Track systolic blood pressure, diastolic blood pressure, total testosterone, and free testosterone while you're running PT-141 so you can catch any drift early and adjust before it becomes a problem. Add these to your REGEN biomarker dashboard and re-check on your normal cadence.
Contraindications
- uncontrolled hypertension
- cardiovascular disease
- pregnancy
References
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder · Kingsberg SA, et al. · 2019
- Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908. · Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA · 2019
- Safety Profile of Bremelanotide Across the Clinical Development Program. · Clayton AH, Kingsberg SA, Portman D et al. · 2022
- The neurobiology of bremelanotide for the treatment of hypoactive ... · Pfaus JG, Sadiq A, Spana C, Clayton AH · 2022
- Clayton AH, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol. 2019;134(5):909-917. · Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH · 2019
- Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. · Simon JA, Kingsberg SA, Portman D et al. · 2022